{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:07:21Z","timestamp":1776121641293,"version":"3.50.1"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871640, 82172255"],"award-info":[{"award-number":["81871640, 82172255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12019116"],"award-info":[{"award-number":["SHDC12019116"]}],"id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The SARS-CoV-2 Omicron (B.1.1529) variant was designated as a variant of concern (VOC) by the World Health Organization (WHO) on November 26, 2021. Within two months, it had replaced the Delta variant and had become the dominant circulating variant around the world. The Omicron variant possesses an unprecedented number of mutations, especially in the spike protein, which may be influencing its biological and clinical aspects. Preliminary studies have suggested that increased transmissibility and the reduced protective effects of neutralizing antibodies have contributed to the rapid spread of this variant, posing a significant challenge to control the coronavirus disease 2019 (COVID-19) pandemic. There is, however, a silver lining for this wave of the Omicron variant. A lower risk of hospitalization and mortality has been observed in prevailing countries. Booster vaccination also has ameliorated a significant reduction in neutralization. Antiviral drugs are minimally influenced. Moreover, the functions of Fc-mediated and T-cell immunity have been retained to a great extent, both of which play a key role in preventing severe disease.<\/jats:p>","DOI":"10.3389\/fimmu.2022.877101","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:36:51Z","timestamp":1651214211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":92,"title":["SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance"],"prefix":"10.3389","volume":"13","author":[{"given":"Yifei","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weien","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yide","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxue","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"B1","unstructured":"COVID-19 Weekly Epidemiological Update2022"},{"key":"B2","unstructured":"2022"},{"key":"B3","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern"},{"key":"B4","unstructured":"Genomic Epidemiology of Novel Coronavirus2022"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00100-3","article-title":"COVID-19 Will Continue But the End of the Pandemic Is Near","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.01.005","article-title":"SARS-CoV-2 Prolonged Infection During Advanced HIV Disease Evolves Extensive Immune Escape","volume":"30","author":"Cele","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgg.2021.12.003","article-title":"Evidence for a Mouse Origin of the SARS-CoV-2 Omicron Variant","volume":"48","author":"Wei","year":"2021","journal-title":"J Genet Genomics = Yi Chuan xue bao"},{"key":"B9","unstructured":"COVID Data Tracker"},{"key":"B10","unstructured":"PANGO Lineages: Latest Epidemiological Lineages of SARS-CoV-22021"},{"key":"B11","unstructured":"Per-Variant2022"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.02.22271767","article-title":"Estimating Relative Generation Times and Relative Reproduction Numbers of Omicron BA.1 and BA.2 With Respect to Delta in Denmark","author":"Ito","year":"2022","journal-title":"medRxiv"},{"key":"B13","unstructured":"SARS-CoV-2 Variants of Concern and Variants Under Investigation in England: Technical Briefing 392022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00001-9","article-title":"Generation Time of the Alpha and Delta SARS-CoV-2 Variants: An Epidemiological Analysis","volume":"22","author":"Hart","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.07.479306","article-title":"Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of Antiviral Agents Against the SARS-CoV-2 Omicron Subvariant BA.2","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum Neutralization of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 in Patients Receiving Monoclonal Antibodies","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.07.479349","article-title":"Omicron BA.2 Specifically Evades Broad Sarbecovirus Neutralizing Antibodies","author":"Cao","year":"2022","journal-title":"bioRxiv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa: A Data Linkage Study","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.13.22272308","article-title":"Duration of mRNA Vaccine Protection Against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar","author":"Chemaitelly","year":"2022","journal-title":"medRxiv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural Basis of Receptor Recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human Ace2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron Extensively But Incompletely Escapes Pfizer BNT162b2 Neutralization","volume":"602","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 Entry Into Cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.19.956581","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive Mapping of Mutations in the SARS-CoV-2 Receptor-Binding Domain That Affect Recognition by Polyclonal Human Plasma Antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 Spike 69\/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y","article-title":"In Vivo Monoclonal Antibody Efficacy Against SARS-CoV-2 Variant Strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c07965","article-title":"Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants","volume":"143","author":"Bai","year":"2021","journal-title":"J Am Chem Society"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1139","article-title":"Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants","volume":"373","author":"Yuan","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron Escapes the Majority of Existing SARS-CoV-2 Neutralizing Antibodies","volume":"602","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.01.001","article-title":"Receptor Binding and Complex Structures of Human ACE2 to Spike RBD From Omicron and Delta SARS-CoV-2","volume":"185","author":"Han","year":"2022","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.17.157982","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001237","article-title":"Cryo-Electron Microscopy Structures of the N501Y SARS-CoV-2 Spike Protein in Complex With ACE2 and 2 Potent Neutralizing Antibodies","volume":"19","author":"Zhu","year":"2021","journal-title":"PloS Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.69091","article-title":"N501Y Mutation of Spike Protein in SARS-CoV-2 Strengthens its Binding to Receptor ACE2","volume":"10","author":"Tian","year":"2021","journal-title":"eLife"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody Resistance of SARS-CoV-2 Variants B","volume":"593","author":"Wang","year":"2021","journal-title":"1.351 B.1.1.7 Nat"},{"key":"B41","doi-asserted-by":"publisher","first-page":"167058","DOI":"10.1016\/j.jmb.2021.167058","article-title":"Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants","volume":"433","author":"Laffeber","year":"2021","journal-title":"J Mol Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c Mice for Testing Vaccine Efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04245-0","article-title":"The N501Y Spike Substitution Enhances SARS-CoV-2 Infection and Transmission","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00954-4","article-title":"SARS-CoV-2 Variant Prediction and Antiviral Drug Design are Enabled by RBD In Vitro Evolution","volume":"6","author":"Zahradn\u00edk","year":"2021","journal-title":"Nat Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501y.V2 From Neutralization by Convalescent Plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9302","article-title":"Prospective Mapping of Viral Mutations That Escape Antibodies Used to Treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27062","article-title":"Preliminary Report on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Mutation T478K","volume":"93","author":"Di Giacomo","year":"2021","journal-title":"J Med Virology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite","volume":"29","author":"Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.19.427324","article-title":"Neutralizing and Protective Human Monoclonal Antibodies Recognizing the N-Terminal Domain of the SARS-CoV-2 Spike Protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-Terminal Domain Antigenic Mapping Reveals a Site of Vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"109292","DOI":"10.2139\/ssrn.3780277","article-title":"Recurrent Emergence of SARS-CoV-2 Spike Deletion H69\/V70 and Its Role in the Alpha Variant B.1.1.7","volume":"35","author":"Meng","year":"2021","journal-title":"Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03237-4","article-title":"Loss of Furin Cleavage Site Attenuates SARS-CoV-2 Pathogenesis","volume":"591","author":"Johnson","year":"2021","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"msab327","DOI":"10.1093\/molbev\/msab327","article-title":"The Emergence of the Spike Furin Cleavage Site in SARS-CoV-2","volume":"39","author":"Chan","year":"2022","journal-title":"Mol Biol Evol"},{"key":"B56","unstructured":"Centers for Disease Control and Prevention. Science Brief: Omicron (B.1.1.529) Variant2021"},{"key":"B57","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","article-title":"The Furin Cleavage Site in the SARS-CoV-2 Spike Protein Is Required for Transmission in Ferrets","volume":"6","author":"Peacock","year":"2021","journal-title":"Nat Microbiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04266-9","article-title":"Enhanced Fusogenicity and Pathogenicity of SARS-CoV-2 Delta P681R Mutation","volume":"602","author":"Saito","year":"2022","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 Leads to Widespread Escape From Neutralizing Antibody Responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00408-4","article-title":"ACE2: The Major Cell Entry Receptor for SARS-CoV-2","volume":"198","author":"Scialo","year":"2020","journal-title":"Lung"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift","volume":"602","author":"Cameroni","year":"2021","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-021-00863-2","article-title":"SARS-CoV-2 Omicron RBD Shows Weaker Binding Affinity Than the Currently Dominant Delta Variant to Human ACE2","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24868","article-title":"Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves","volume":"327","author":"Maslo","year":"2022","journal-title":"JAMA"},{"key":"B65","unstructured":"SARS-CoV-2 Variants of Concern and Variants Under Investigation in England: Technical Briefing 312021"},{"key":"B66","doi-asserted-by":"publisher","first-page":"o110","DOI":"10.1136\/bmj.o110","article-title":"Covid-19: Omicron Variant is Linked to Steep Rise in Hospital Admissions of Very Young Children","volume":"376","author":"Torjesen","year":"2022","journal-title":"BMJ (Clinical Res ed)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.17.22271030","article-title":"Clinical Severity of Omicron Sub-Lineage BA.2 Compared to BA.1 in South Africa","author":"Wolter","year":"2022","journal-title":"medRxiv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2023329","article-title":"SARS-CoV-2 Omicron Variant Shows Less Efficient Replication and Fusion Activity When Compared With Delta Variant in TMPRSS2-Expressed Cells","volume":"11","author":"Zhao","year":"2022","journal-title":"Emerging Microbes Infections"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41467-022-28089-y","article-title":"Viral Infection and Transmission in a Large, Well-Traced Outbreak Caused by the SARS-CoV-2 Delta Variant","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1191837\/v1","article-title":"SARS-CoV-2 Omicron Spike Mediated Immune Escape and Tropism Shift","author":"Gupta","year":"2022","journal-title":"Res Square"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and Transmission of SARS-CoV-2 in Golden Hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.02.474743","article-title":"Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters","author":"McMahan","year":"2022","journal-title":"bioRxiv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.21.21258528","article-title":"Correlates of Protection Against Symptomatic and Asymptomatic SARS-CoV-2 Infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of Convalescent and Vaccine Serum Against SARS-CoV-2 Omicron","volume":"602","author":"Carre\u00f1o","year":"2021","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant Following Homologous and Heterologous CoronaVac or BNT162b2 Vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma Neutralization of the SARS-CoV-2 Omicron Variant","volume":"386","author":"Schmidt","year":"2022","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron Variant Is Highly Resistant Against Antibody-Mediated Neutralization: Implications for Control of the COVID-19 Pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralization","volume":"602","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced Neutralisation of SARS-CoV-2 Omicron B.1.1.529 Variant by Post-Immunisation Serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet (London England)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 Omicron Variant Neutralization in Serum From Vaccinated and Convalescent Persons","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 Vaccine Against Omicron Variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23641","article-title":"Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel","volume":"327","author":"Spitzer","year":"2022","journal-title":"JAMA"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01575-4","article-title":"Viral Loads of Delta-Variant SARS-CoV-2 Breakthrough Infections After Vaccination and Booster With BNT162b2","volume":"27","author":"Levine-Tiefenbrun","year":"2021","journal-title":"Nat Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.12.014","article-title":"COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients With Cancer","volume":"40","author":"Zeng","year":"2022","journal-title":"Cancer Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2021.12.15.21267805","DOI":"10.1101\/2021.12.15.21267805","article-title":"Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization","author":"Doria-Rose","year":"2021","journal-title":"medRxiv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron Variant Showed Lower Neutralizing Sensitivity Than Other SARS-CoV-2 Variants to Immune Sera Elicited by Vaccines After Boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerging Microbes Infections"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-022-00375-5","article-title":"Reduced Sensitivity of SARS-CoV-2 Omicron Variant to Antibody Neutralization Elicited by Booster Vaccination","volume":"8","author":"Yu","year":"2022","journal-title":"Cell Discov"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7842","article-title":"Antibodies Elicited by SARS-CoV-2 Infection or mRNA Vaccines Have Reduced Neutralizing Activity Against Beta and Omicron Pseudoviruses","author":"Sievers","year":"2022","journal-title":"Sci Trans Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119426","article-title":"Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant","volume":"386","author":"Zhao","year":"2022","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine Against Omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural Biology of SARS-CoV-2 and Implications for Therapeutic Development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of Antibodies and Antiviral Drugs Against Covid-19 Omicron Variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","article-title":"An Update on Drugs With Therapeutic Potential for SARS-CoV-2 (COVID-19) Treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resistance Updates Rev Commentaries Antimicrobial Anticancer Chemother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201993","article-title":"Antibody Potency, Effector Function, and Combinations in Protection and Therapy for SARS-CoV-2 Infection In Vivo","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J Exp Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human Neutralizing Antibodies Against SARS-CoV-2 Require Intact Fc Effector Functions for Optimal Therapeutic Protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.01.001","article-title":"mRNA-1273 Vaccine-Induced Antibodies Maintain Fc Effector Functions Across SARS-CoV-2 Variants of Concern","volume":"55","author":"Kaplonek","year":"2022","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and Effectiveness of mRNA BNT162b2 Vaccine Against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet (London England)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01696-18","article-title":"Broadly Cross-Reactive, Nonneutralizing Antibodies Against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection Against Lethal Viral Challenge In Mice","volume":"93","author":"Asthagiri Arunkumar","year":"2019","journal-title":"J Virol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e1009724","DOI":"10.1371\/journal.ppat.1009724","article-title":"A Non-Neutralizing Antibody Broadly Protects Against Influenza Virus Infection by Engaging Effector Cells","volume":"17","author":"Ko","year":"2021","journal-title":"PloS Pathogens"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7424","article-title":"Broad Neutralization of SARS-Related Viruses by Human Monoclonal Antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143380","article-title":"Recent Endemic Coronavirus Infection Is Associated With Less-Severe COVID-19","volume":"131","author":"Sagar","year":"2021","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T Cell Immunity in Convalescent Individuals With Asymptomatic or Mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj6824","article-title":"Escape From Recognition of SARS-CoV-2 Variant Spike Epitopes But Overall Preservation of T Cell Immunity","volume":"14","author":"Riou","year":"2022","journal-title":"Sci Trans Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00838-5","article-title":"T Cell Epitopes in SARS-CoV-2 Proteins Are Substantially Conserved in the Omicron Variant","volume":"19","author":"Choi","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-Specific T Cells Cross-Recognize the Omicron Variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.12.473243","article-title":"COVID-19 Vaccine Booster Induces a Strong CD8<sup<+<\/sup< T Cell Response Against Omicron Variant Epitopes in HLA-A*02:01<sup<+<\/sup< Individuals","author":"Nguyen","year":"2022","journal-title":"bioRxiv"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.17.476685","article-title":"Nirmatrelvir, Molnupiravir, and Remdesivir Maintain Potent In Vitro Activity Against the SARS-CoV-2 Omicron Variant","author":"Rosales","year":"2022","journal-title":"bioRxiv"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201607","article-title":"Neutralization Profile After Recovery From SARS-CoV-2 Omicron Infection","author":"R\u00f6ssler","year":"2022","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.03.029","article-title":"SARS-CoV-2 Omicron Triggers Cross-Reactive Neutralization and Fc Effector Functions in Previously Vaccinated, But Not Unvaccinated Individuals","author":"Richardson","year":"","journal-title":"Cell Host Microbe"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal Vaccines - Fortifying the Frontiers","volume":"22","author":"Lavelle","year":"2021","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.877101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:36:56Z","timestamp":1651214216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.877101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":115,"alternative-id":["10.3389\/fimmu.2022.877101"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.877101","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"article-number":"877101"}}